Title |
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
|
---|---|
Published in |
American Heart Journal, December 2009
|
DOI | 10.1016/j.ahj.2009.09.017 |
Pubmed ID | |
Authors |
Gregory G. Schwartz, Anders G. Olsson, Christie M. Ballantyne, Phillip J. Barter, Ingar M. Holme, David Kallend, Lawrence A. Leiter, Eran Leitersdorf, John J.V. McMurray, Prediman K. Shah, Jean-Claude Tardif, Bernard R. Chaitman, Regina Duttlinger-Maddux, John Mathieson, on behalf of the dal-OUTCOMES Committees and Investigators |
Abstract |
Despite contemporary therapies for acute coronary syndrome (ACS), morbidity and mortality remain high. Low levels of high-density lipoprotein (HDL) cholesterol are common among patients with ACS and may contribute to ongoing risk. Strategies that raise levels of HDL cholesterol, such as inhibition of cholesterol ester transfer protein (CETP), might reduce risk after ACS. Dal-OUTCOMES is a multicenter, randomized, double-blind, placebo-controlled trial designed to test the hypothesis that CETP inhibition with dalcetrapib reduces cardiovascular morbidity and mortality in patients with recent ACS. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | 1% |
Unknown | 69 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 16 | 23% |
Researcher | 13 | 19% |
Student > Bachelor | 7 | 10% |
Other | 5 | 7% |
Professor | 4 | 6% |
Other | 14 | 20% |
Unknown | 11 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 28 | 40% |
Agricultural and Biological Sciences | 10 | 14% |
Biochemistry, Genetics and Molecular Biology | 5 | 7% |
Neuroscience | 3 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 5 | 7% |
Unknown | 17 | 24% |